Despite deep discounts, Humira biosimilars are priced higher than the originator’s original price
Despite significant discounts from the current price of Humira (adalimumab), introductory prices of the biosimilars adalimumab are still double the originator’s introductory price, according to a study published in JAMA network open. Humira can be administered with a pre-filled syringe or an auto-injector pen. Throughout 2023, 9 FDA-approved adalimumab biosimilars are expected to enter the … Read more